ZLAB - Zai Lab Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
23.36
-0.08 (-0.34%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close23.44
Open23.50
Bid22.75 x 1100
Ask24.66 x 1000
Day's Range23.33 - 23.91
52 Week Range17.85 - 35.74
Volume38,055
Avg. Volume87,606
Market Cap1.181B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.32
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.00
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that William Liang has been appointed Chief Commercial Officer, reporting to Dr. Samantha Du, Zai Lab’s Chief Executive ­­Officer. Mr. Liang brings more than two decades of experience in the pharmaceutical industry, heading China and regional commercial operations of global companies, with expertise in commercial launch, strategy and operations. William was instrumental in establishing market-leading oncology and other franchises in China for AstraZeneca and Roche, overseeing commercial success of top selling drugs such as, but not limited to, Tagrisso®, Iressa®, Tarceva®, MabThera®, Herceptin®, Avastin® and Pegasys®.

  • GlobeNewswire25 days ago

    Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications

    Candidate to expand Zai Lab’ s early-stage R&D programs, with an anticipated IND Filing for clinical studies in psoriasis in 2019. SHANGHAI, China and CAMBRIDGE, United Kingdom, May 30, 2018-- Zai Lab ...

  • GlobeNewswire25 days ago

    Zai Lab Announces Presentations at June Investor Conferences

    SHANGHAI, China, May 29, 2018-- Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, today announced its participation in two upcoming investor conferences. Jefferies 2018 Global Healthcare ...

  • GlobeNewswirelast month

    Zai Lab Announces Early Completion of Enrollment for ZL-2306 PK Study

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that it has completed enrollment ahead of schedule of the pharmacokinetics (PK) study for ZL-2306 for Chinese patients with platinum-sensitive ovarian cancer. “We are pleased that our pharmacokinetics study, initiated in late 2017 with the purpose of establishing the PK profile of ZL-2306 in Chinese patients, has successfully completed enrollment three months ahead of schedule,” said Samantha Du, Zai Lab’s Chief Executive Officer. “We expect to finalize the data from this study by mid-2018, also earlier than planned, and look forward to continuing our active dialogue with the regulatory authorities to bring ZL-2306 to Chinese patients with ovarian cancer as quickly as possible.” In China the current standard of care to treat ovarian cancer consists of radical surgery and chemotherapy.

  • GlobeNewswire2 months ago

    Zai Lab Reports Full Year 2017 Financial Results and Corporate Update

    --Zai Lab to Host Conference Call and Webcast Today at 8:30 a.m. ET--. SHANGHAI, China, May 02, 2018-- Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, today will provide an overview ...

  • ACCESSWIRE2 months ago

    Blog Exposure - Zai Lab Inks Exclusive License Deal with Entasis for ETX2514 in the Asia/Pacific Region

    LONDON, UK / ACCESSWIRE / April 27, 2018 / Active-Investors.com has just released a free research report on Zai Lab Ltd (NASDAQ: ZLAB). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZLAB as the Company's latest news hit the wire. On April 25, 2018, the Company announced that it has inked an exclusive license agreement with Entasis Therapeutics Holdings Inc. ("Entasis") for the rights to ETX2514, which is a novel broad-spectrum intravenous inhibitor of β-lactamases, in the Asia/Pacific region.

  • Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514
    Business Wire2 months ago

    Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514

    Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced an exclusive license agreement for ETX2514 in the Asia-Pacific region and a global strategic development collaboration. Entasis is developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of a variety of serious multidrug-resistant infections caused by Acinetobacter baumannii, representing a healthcare challenge of global importance with over 200,000 occurrences estimated in China each year.

  • GlobeNewswire2 months ago

    Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514

    Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced an exclusive license agreement for ETX2514 in the Asia-Pacific region and a global strategic development collaboration. Entasis is developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of a variety of serious multidrug-resistant infections caused by Acinetobacter baumannii, representing a healthcare challenge of global importance with over 200,000 occurrences estimated in China each year.

  • GlobeNewswire2 months ago

    Zai Lab Limited Announces Presentations at May Investor Conferences

    SHANGHAI, China, April 24, 2018-- Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, today announced that members of the senior management team will participate at two upcoming investor ...

  • Reuters4 months ago

    China's Tasly to list biotech arm in $1 bln Hong Kong IPO - sources

    China's Tasly Pharmaceutical Group is planning to list its biopharma unit in Hong Kong to raise about $1 billion, in what is likely to be the largest biotech float in the city this year, people with knowledge of the matter said. The plan comes as Hong Kong Exchanges and Clearing , the city's exchange operator, is proposing changes to its listing rules to woo early-stage drug developers. Tianjin-based Tasly, well known for producing traditional Chinese medicines, aims to list its wholly owned biopharma arm - Shanghai Tasly Pharmaceutical in the second half of 2018, said the people.

  • Should You Be Concerned About Zai Lab Limited’s (NASDAQ:ZLAB) Shareholders?
    Simply Wall St.4 months ago

    Should You Be Concerned About Zai Lab Limited’s (NASDAQ:ZLAB) Shareholders?

    In this analysis, my focus will be on developing a perspective on Zai Lab Limited’s (NASDAQ:ZLAB) latest ownership structure, a less discussed, but important factor. A company’s ownership structure isRead More...

  • Zai Lab Limited (ZLAB): Is Now The Time To Bet On Healthcare?
    Simply Wall St.7 months ago

    Zai Lab Limited (ZLAB): Is Now The Time To Bet On Healthcare?

    Zai Lab Limited (NASDAQ:ZLAB), a USD$1.32B small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...

  • Why Zai Lab Limited’s (ZLAB) Investor Composition Impacts Your Returns
    Simply Wall St.7 months ago

    Why Zai Lab Limited’s (ZLAB) Investor Composition Impacts Your Returns

    In this article, I’m going to take a look at Zai Lab Limited’s (NASDAQ:ZLAB) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • 24/7 Wall St.9 months ago

    IPO News This Week: Roku, PQ Group Lead 7 Offerings Due Out

    Seven IPOs are scheduled to hit the public markets this week, including video streaming service Roku and specialty chemicals firm PQ Group, both valued at more than $1 billion before their IPOs.